Patents by Inventor Gyula Lukacs
Gyula Lukacs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230364093Abstract: A pharmaceutical composition containing palbociclib tosylate and letrozole, in which palbociclib tosylate and letrozole are in one dosage unit, and the particles of the active ingredient palbociclib tosylate and letrozole are not separated from each other, and the production of the pharmaceutical preparation, the granule containing palbociclib tosylate and letrozole, the use of the pharmaceutical preparation and special blister packaging that facilitates the use of a specific dosage regimen.Type: ApplicationFiled: February 9, 2023Publication date: November 16, 2023Applicant: EGIS Gyógyszergyár Zrt.Inventors: László UGRAI, Gyula LUKÁCS
-
Patent number: 11672804Abstract: A pharmaceutical composition containing palbociclib tosylate and letrozole, in which palbociclib tosylate and letrozole are in one dosage unit, and the particles of the active ingredient palbociclib tosylate and letrozole are not separated from each other, and the production of the pharmaceutical preparation, the granule containing palbociclib tosylate and letrozole, the use of the pharmaceutical preparation and special blister packaging that facilitates the use of a specific dosage regimen.Type: GrantFiled: August 19, 2022Date of Patent: June 13, 2023Assignee: EGIS Gyógyszergyár Zrt.Inventors: László Ugrai, Gyula Lukács
-
Publication number: 20190040037Abstract: The object of the invention relates to a novel group of compounds of general formula 20 that may be used as an intermediate for the production of the pharmaceutical active substance pomalidomide. The object of the invention also relates to a novel, cost-effective, productive method for the production of pomalidomide that can also be implemented on industrial scales via the novel compound of formula 20 according to the invention.Type: ApplicationFiled: January 19, 2017Publication date: February 7, 2019Applicant: EGIS GYOGYSZERGYAR ZRT.Inventors: Balazs VOLK, Katalin KATAINE FADGYAS, Gyula LUKACS, Maria TOTHNE LAURITZ, Andras DANCSO, Imre KIRALY, Laszlo PALOTAI, Robert KORMANY
-
Patent number: 10023566Abstract: The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.Type: GrantFiled: May 26, 2015Date of Patent: July 17, 2018Assignee: EGIS GYOGYSZERGYAR ZRTInventors: Ede Laszlo Marvanyos, Attila Virag, Tamas Gregor, Balazs Volk, Maria Tothne Lauritz, Laszlo Pongo, Balazs Peregi, Gyula Lukacs, Zoltan Varga, Andras Dancso
-
Publication number: 20170183334Abstract: The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.Type: ApplicationFiled: May 26, 2015Publication date: June 29, 2017Applicant: EGIS GYOGYSZERGYAR ZRTInventors: Ede Laszlo MARVANYOS, Attila VIRAG, Tamas GREGOR, Balazs VOLK, Maria TOTHNE LAURITZ, Laszlo PONGO, Balazs PEREGI, Gyula LUKACS, Zoltan VARGA, Andras DANCSO
-
Patent number: 9556163Abstract: The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The invention also relates to intermediates formed in the above process.Type: GrantFiled: May 4, 2012Date of Patent: January 31, 2017Assignee: EGIS Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagInventors: Eva Sipos, Gyorgyi Kovanyine Lax, Balazs Havasi, Balazs Volk, Gyorgy Krasznai, Gyorgy Ruzsics, Jozsef Barkoczy, Maria Tothne Lauritz, Gyula Lukacs, Andras Boza, Laszlo Jozsef Hegedus, Maria Julia Taborine Toth, Eva Pecsi
-
Patent number: 9321733Abstract: The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis.Type: GrantFiled: November 16, 2011Date of Patent: April 26, 2016Assignee: EGIS Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagInventors: Imre Markovits, Ferenc Jurak, Gyorgyi Kovanyine Lax, Csaba Hamori, Balazs Havasi, Eva Sipos, Balazs Volk, Zsolt Runge, Krisztina Fodorne Kocsmar, Gyula Lukacs, Katalin Kataine Fadgyas, Monika Mezovari
-
Patent number: 9260421Abstract: The present invention relates to a process for the preparation of dabigatran etexilate of the formula or pharmaceutically accepted salts thereof.Type: GrantFiled: May 10, 2012Date of Patent: February 16, 2016Assignee: EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAGInventors: Imre Kiraly, Tibor Szabo, Gyula Simig, Balazs Volk, Laszlo Szlavik, Jozsef Barkoczy, Gyorgy Ruzsics, Gyula Lukacs, Laszlo Pongo, Andras Boza, Maria Tothne Lauritz, Maria Kovacs
-
Patent number: 9040696Abstract: The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.Type: GrantFiled: November 29, 2011Date of Patent: May 26, 2015Assignee: EGIS Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagInventors: Marta Porcs-Makkay, Ferenc Lorant Bartha, Gyorgy Krasznai, Balazs Volk, Gyorgy Ruzsics, Laszlo Pongo, Gyula Lukacs, Tibor Szabo, Jozsef Barkoczy, Jozsef Debreczeni, Adrienn Keszthelyi, Angela Pandur, Eniko Molnar, Matyas Milen, Maria Tothne Lauritz
-
Patent number: 8883860Abstract: A method for purifying diatomaceous earth, whose natural colloidal structure is retained, which includes preparing a suspension of diatomaceous earth in a liquid wherein diatomaceous earth is insoluble, separating diatomaceous earth from the suspension, treating diatomaceous earth with an inorganic or organic acid, heat-treating the thus obtained product at a temperature not higher than 300° C., subjecting the product obtained to oxidative treatment and drying the purified product.Type: GrantFiled: October 12, 2011Date of Patent: November 11, 2014Assignees: Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag, ONP Holdings SEInventors: Endre Mikulásik, Tamás Spaits, Kálmán Nagy, Gyula Lukács, Imre Markovits, Krisztina Fodorné Kocsmár, Livia Gregorné Boros, Tamás Mórász, László Szlávik, Máté Hudák, Gyöngyi Heréb, Réka Eszter Puskás, Zoltán Varga, Imre Kapui, György Clementis, Gábor Attila Bacher, Beatrix Bánkövi, Gitta Kiss, Ottó Albrecht
-
Publication number: 20140155614Abstract: The present invention relates to a process for the preparation of dabigatran etexilate of the formula or pharmaceutically accepted salts thereof.Type: ApplicationFiled: May 10, 2012Publication date: June 5, 2014Applicant: EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAGInventors: Imre Kiraly, Tibor Szabo, Gyula Simig, Balazs Volk, Laszlo Szlavik, Jozsef Barkoczy, Gyorgy Ruzsics, Gyula Lukacs, Laszlo Pongo, Andras Boza, Maria Tothne Lauritz, Maria Kovacs
-
Publication number: 20140142303Abstract: The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The process is characterized by the reactions according to claim 1. The invention also relates to intermediates formed in the above process.Type: ApplicationFiled: May 4, 2012Publication date: May 22, 2014Applicant: EGIS Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagInventors: Eva Sipos, Gyorgyi Kovanyine Lax, Balazs Havasi, Balazs Volk, Gyorgy Krasznai, Gyorgy Ruzsics, Jozsef Barkoczy, Maria Tothne Lauritz, Gyula Lukacs, Andras Boza, Laszlo Jozsef Hegedus, Maria Julia Taborine Toth, Eva Pecsi
-
Publication number: 20130296353Abstract: The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis.Type: ApplicationFiled: November 16, 2011Publication date: November 7, 2013Applicant: EGIS Gyogyszergyar Nyilvanosan Mukodo Reszvenytar- sasagInventors: Imre Markovits, Ferenc Jurak, Gyorgyi Kovanyine Lax, Csaba Hamori, Balazs Havasi, Eva Sipos, Balazs Volk, Zsolt Runge, Krisztina Fodorne Kocsmar, Gyula Lukacs, Katalin Kataine Fadgyas, Monika Mezovari
-
Publication number: 20130281694Abstract: The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.Type: ApplicationFiled: November 29, 2011Publication date: October 24, 2013Applicant: EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENY-TARSASAGInventors: Marta Porcs-Makkay, Ferenc Lorant Bartha, Gyorgy Krasznai, Balazs Volk, Gyorgy Ruzsics, Laszlo Pongo, Gyula Lukacs, Tibor Szabo, Jozsef Barkoczy, Jozsef Debreczeni, Adrienn Keszthelyi, Angela Pandur, Eniko Molnar, Matyas Milen, Maria Tothne Lauritz
-
Publication number: 20130225695Abstract: The present invention is related to a method for purifying diatomaceous earth wherein the natural colloidal structure of the material is retained, which comprises preparing a suspension of diatomaceous earth in a liquid wherein diatomaceous earth is insoluble, separating diatomaceous earth from the suspension, treating diatomaceous earth with an inorganic or organic acid, heat-treating the thus obtained product at a temperature not higher than 300° C., subjecting the product obtained to oxidative treatment and drying the purified product. The invention also relates to a product obtainable by the above-mentioned method.Type: ApplicationFiled: October 12, 2011Publication date: August 29, 2013Applicants: ONP HOLDINGS SE, EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAGInventors: Endre Mikulásik, Tamás Spaits, Kálmán Nagy, Gyula Lukács, Imre Markovits, Krisztina Fodorné Kocsmár, Livia Gregorné Boros, Tamás Mórász, László Szlávik, Máté Hudák, Gyöngyi Heréb, Réka Eszter Puskás, Zoltán Varga, Imre Kapui, György Clementis, Gábor Attila Bacher, Beatrix Bánkövi, Gitta Kiss, Ottó Albrecht
-
Patent number: 8394993Abstract: The invention relates to a process for the preparation of cyclopropyl benzyl ketone compounds of formula (II) wherein R1 represents fluorine or chlorine atom or C1-4 alkoxy group, by the reaction of a Grignard reagent, obtained from the reaction of compound of formula (V), wherein X represents chlorine or fluorine atom, with the compound of formula (IV), wherein R2 represents C1-4 alkyl group, having a straight or branched chain. The process can be applied preferably on industrial scale. Compound of formula (II), wherein R represents a fluorine atom in position 2 is an intermediate of the preparation process of prasugrel, which is a platelet inhibitor used in the therapy.Type: GrantFiled: November 27, 2008Date of Patent: March 12, 2013Assignee: Egis Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagInventors: Tibor Mezei, Gyula Lukács, Enikó Molnár, József Barkóczy, Balázs Volk, Márta Porcs-Makkay, János Szulágyi, Mária Vajjon
-
Publication number: 20120108607Abstract: The present invention relates to the enantiomers of 5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-1-yl]butyl}-3-ethyl-1,3-dihydro-2H-indol-2-one of the Formula (II) pharmaceutically acceptable salts thereof, process for the preparation thereof, medicinal products containing said enantiomers and the use thereof and their pharmaceutically acceptable salts in the treatment of the disorders of the central nervous system.Type: ApplicationFiled: February 5, 2010Publication date: May 3, 2012Inventors: Balázs Volk, József Barkóczy, István Gacsalyi, Elemér Fogassy, József Schindler, Gábor Gigler, Hajnalka Kompagne, Iidikó Nagyné Gyoenos, Katalin Pallagi, Márta Porcs-Makkay, Gábor Szénási, Tibor Mezel, Gyula Lukács, Gyoergy Lévay, András Egyed, László Gábor Hársing
-
Publication number: 20120035162Abstract: The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam.Type: ApplicationFiled: October 12, 2011Publication date: February 9, 2012Inventors: Tibor MEZEI, Gyula Simig, Enikó Molnár, Gyula Lukács, Márta Porcs-Makkay, Balázs Volk, Valéria Hofmanné Fekete, Kálmán Nagy, Norbert Mesterházy, György Krasznai, Györgyi Vereczkeyné Donáth, Gyuláné Körtvélyessy, Éva Pécsi
-
Patent number: 8097616Abstract: The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium sait monohydrate is produced. Said sait is subsequently treated with mineral or organic acid to yield high-purity meloxicam.Type: GrantFiled: December 16, 2005Date of Patent: January 17, 2012Assignee: Egis Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagInventors: Tibor Mezei, Gyula Simig, Enikó Molnár, Gyula Lukács, Márta Porcs-Makkay, Balázs Volk, Valéria Hofmanné Fekete, Kálmán Nagy, Norbert Mesterházy, György Krasznai, Györgyi Vereczkeyné Donáth, Gyuláné Körtvélyessy, Éva Pécsi
-
Patent number: 7960558Abstract: The compounds of the general Formula (I), wherein R1 is aryl or alkyl; R2 represents alkyl; R3 represents alkyl or aralkyl, are valuable pharmaceutical intermediates, which can be prepared by reacting a compound of the general Formula (IV) (wherein the definitions of R1 and R2 are as above), with at least 2 molar equivalents of the compound of the general Formula (VI) (wherein X represents halogen or tertiary butyloxycarbonyloxy group and R3 is as defined above). The known compounds of the general Formula (II) (wherein R1 and R2 are as defined above) are prepared by reacting the compounds of the general Formula (I) with thionyl chloride. The compounds of the general Formula (I) are new intermediates useful in the synthesis of pharmaceutically active ingredients, particularly in the preparation of ACE-inhibitors, e.g. enalapril, perindopril or ramipril.Type: GrantFiled: May 11, 2007Date of Patent: June 14, 2011Assignee: Egis Gyogyszergyar Nyilvanosan Mukodo ReszvenytarsasagInventors: Márta Porcs-Makkay, Gyula Simig, Tibor Mezei, Angéla Veressné Pandur, Gyula Lukács